Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147416 | 0.88 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1SSTR5 | |
| SCHEMBL20206008 | 0.83 | OPRM1 (0.47) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20158624 | 0.83 | OPRM1 (0.47) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13231734 | 0.80 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1SSTR5 | |
| SCHEMBL28914608 | 0.77 | OPRL1 (0.43) | OPRM1OPRD1OPRK1OPRL1SSTR5 | |
| SCHEMBL3814747 | 0.76 | OPRM1 (0.45) | OPRM1OPRD1OPRK1OPRL1SSTR5 | |
| SCHEMBL7328780 | 0.75 | SLC6A4 (0.57) | OPRM1OPRD1OPRK1OPRL1GRIN2B | |
| SCHEMBL7328785 | 0.75 | SLC6A4 (0.57) | OPRM1OPRD1OPRK1OPRL1GRIN2B | |
| SCHEMBL7329242 | 0.74 | GRIN2B (0.56) | OPRM1OPRD1OPRK1OPRL1SSTR5 | |
| SCHEMBL9963240 | 0.74 | GRIN2B (0.54) | OPRM1OPRD1OPRK1OPRL1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | OPRM1 3497/4885OPRD1 2909/4885OPRK1 2369/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | OPRM1 3497/4885OPRD1 2909/4885OPRK1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.